PMT PennyMac reports Q4 2025 earnings per share 197 percent above estimates shares rise 142 percent today MUZEU Muzero outlines new crosssector strategic acquisition priorities during its latest quarterly earnings call SYRE Spyre Therapeutics reports narrower Q4 2025 pershare loss than consensus forecasts with shares edging higher in todays trading